|
KMID : 0869620180350020154
|
|
Journal of Korean Society of Hospital Pharmacists
2018 Volume.35 No. 2 p.154 ~ p.176
|
|
|
The Drug Use Evaluation of a Fixed-dose Combination with Oxycodone and Naloxone for the Baseline Pain Control in Cancer Patients
|
|
Park Seon-Hee
Baek In-Hwan
Sohn Kie-Ho
|
|
|
Abstract
|
|
|
Purpose : There is compelling evidence that the fixed-dose combination with oxycodone and naloxone (Targin PR tab®) is useful for the management of baseline pain control for cancer patients. The purpose of the study was to evaluate the appropriate use of Targin PR tab® in the cancer-related pain management.
Methods : The retrospective study was conducted in cancer patients who were prescribed the Targin PR tab® (5/2.5 mg, 10/5 mg, 20/10 mg, 40/20 mg) from January 2016 to August 2016, and who were then reviewed using the self-developed Drug Use Evaluation (DUE) criteria.
Results : 86 patients were finally enrolled in the study. The justification of use for the study was with 70 cases (81.4%). The adequacy of the initial dose and usage was noted at 54 cases (62.8%) and 79 cases (91.9%), respectively. The Targin PR tab® was prescribed to 32 patients (37.2%) who were contraindicated in the use of this drug. Notably, the drug-related adverse effects were reported in 24 cases (27.9%). It is noted that most of the side effects experienced by participants in this study were from gastrointestinal events, such as constipation. In 72 of the cases (83.7%), the Targin PR tab® was prescribed with other drugs, potentially changing its PK/PD profile. The compliance rates of the initial pain evaluation during the patient hospitalization stage were 85 cases (98.8%). However, the appropriate control of breakthrough pain and reevaluation of pain showed in 64 cases (74.4%). In 52 cases (60.5%), the dose or type of drug is effectively modified according to the appropriate pain control guidelines in the cancer patients.
Conclusion : The justification of the use indicated in accordance with the medication was considered as highly suitable in this case. However, according to regular pain evaluation, the modification of the dose and the associated formulation were slightly inadequate. These results suggest the need to upgrade the management of the cancer-related-pain to help cancer patients improve their quality of life with the use of this drug therapy.
|
|
|
KEYWORD
|
|
|
Oxycodone, Drug use evaluation, Retrospective analysis, Pain control
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|